Please provide your email address to receive an email when new articles are posted on . Use of vorapaxar, a PAR-1 antagonist, was associated with reduced acute limb ischemia in patients with ...

SAN DIEGO — New analyses of the TRA 2P-TIMI 50 trial showed that vorapaxar use was associated with reductions in acute limb ischemia, peripheral revascularization and recurrent major CV events in ...

June 20, 2012 (Dallas, Texas) — New data from the peripheral arterial disease (PAD) subgroup of the TRA 2°P TIMI 50 trial have suggested that the protease-activated receptor 1 (PAR-1) antagonist ...

Surmodics (Nasdaq:SRDX) announced results from a sex-specific analysis of real-world patients in a study of its Pounce ...

Acute limb ischemia (ALI) results from a sudden obstruction in the arterial flow to the extremity due to an embolism or thrombosis. Embolic problems result in a greater degree of ischemia than ...

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that early ...

Four Factors Account for Most of Risk Linked to PAD in Men For patients with peripheral artery disease (PAD), treatment with the platelet inhibitor vorapaxar significantly reduces the risk of ...

In a real-world setting, the downstream demands on healthcare resources entailed by first-line use of catheter-directed thrombolysis in nonembolic acute limb ischemia (ALI) make it a less ...

BEAUFORT, S.C.--(BUSINESS WIRE)--A new analysis published by THE SAGE GROUP concludes that ALI represents a substantial market opportunity for pharmaceutical and interventional therapies. “Although ...

Penumbra Inc. (($PEN)) announced an update on their ongoing clinical study. Study Overview: Penumbra Inc. is conducting a study titled ‘STRIDE II: ...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care ...